PDF herunterladen
CC BY 4.0 · Pharmaceutical Fronts 2021; 03(04): e183-e193
DOI: 10.1055/s-0041-1740049
Original Article

Design, Synthesis, and Antidepressant Activity Study of Novel Aryl Piperazines Targeting Both 5-HT1A and Sigma-1 Receptors

Yan-Na Ni
1   School of Chemistry and Chemical Engineering, Shanghai University of Engineering Science, Shanghai, People's Republic of China
2   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Xin-Li Du
2   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Tao Wang
2   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Yuan-Yuan Chen
2   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Xiang-Qing Xu
3   Jiangsu Enhua Pharmaceutical Co., Ltd., Jiangsu, People's Republic of China
,
Song Zhao
3   Jiangsu Enhua Pharmaceutical Co., Ltd., Jiangsu, People's Republic of China
,
Jian-Qi Li
2   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
,
Guan Wang
2   Novel Technology Center of Pharmaceutical Chemistry, Shanghai Institute of Pharmaceutical Industry, China State Institute of Pharmaceutical Industry, Shanghai, People's Republic of China
› Institutsangaben
› Weitere Informationen
   Lizenzen und Reprints


Abstract

A total of 20 novel aryl piperazine derivatives were designed and synthesized, and their structures were confirmed by mass spectrometry and nuclear magnetic resonance analyses. Their 5-HT1A and sigma-1 receptor affinities were determined, and six of them showed high affinities (K i < 20 nmol/L) to both 5-HT1A and sigma-1 targets. Then, metabolic stability (T 1/2) tests of six compounds in rat and human liver microsomes were performed. Our data indicated that compound 27 has both high affinity for 5-HT1A and sigma-1 receptors (5-HT1A: K i = 0.44 nmol/L; sigma-1: K i = 0.27 nmol/L), and good metabolic stability (T 1/2 values are 21.7 and 24.6 minutes, respectively). Interestingly, results from the forced swimming test, mouse tail suspension test, and preliminary pharmacokinetic test suggested the marked antidepressant activity, good pharmacokinetic characteristics, and low toxicity of compound 27 in the two models. In conclusion, compound 27 has great value of further study as an active molecule of antidepressant drugs.

Keywords

5-HT1A receptor - sigma-1 receptor - high affinity - antidepressant

Ethics Statement

The present study was approved by the animal ethics committee and abides by the relevant agreements of the Jiangsu Enhua Pharmaceutical Co., Ltd., Jiangsu, People's Republic of China.




Publikationsverlauf

Eingereicht: 03. September 2021

Angenommen: 09. Oktober 2021

Artikel online veröffentlicht:
25. Dezember 2021

© 2021. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution License, permitting unrestricted use, distribution, and reproduction so long as the original work is properly cited. (https://creativecommons.org/licenses/by/4.0/)

Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany

 

  • References

  • 1 GBD 2016 SDG Collaborators. Measuring progress and projecting attainment on the basis of past trends of the health-related Sustainable Development Goals in 188 countries: an analysis from the Global Burden of Disease Study 2016. Lancet 2017; 390 (10100): 1423-1459
    CrossrefPubMedGoogle Scholar
  • 2 Hindmarch I, Hashimoto K. Cognition and depression: the effects of fluvoxamine, a sigma-1 receptor agonist, reconsidered. Hum Psychopharmacol 2010; 25 (03) 193-200
    CrossrefPubMedGoogle Scholar
  • 3 Kulkarni SK, Dhir A. Current investigational drugs for major depression. Expert Opin Investig Drugs 2009; 18 (06) 767-788
    CrossrefPubMedGoogle Scholar
  • 4 Fournier JC, DeRubeis RJ, Hollon SD. et al. Antidepressant drug effects and depression severity: a patient-level meta-analysis. JAMA 2010; 303 (01) 47-53
    CrossrefPubMedGoogle Scholar
  • 5 Delgado M, Caicoya AG, Greciano V. et al. Anxiolytic-like effect of a serotonergic ligand with high affinity for 5-HT1A, 5-HT2A and 5-HT3 receptors. Eur J Pharmacol 2005; 511 (01) 9-19
    CrossrefPubMedGoogle Scholar
  • 6 McCreary AC, Jones CA. Antipsychotic medication: the potential role of 5-HT(1A) receptor agonism. Curr Pharm Des 2010; 16 (05) 516-521
    CrossrefPubMedGoogle Scholar
  • 7 López JF, Chalmers DT, Little KY, Watson SJAE. A.E. Bennett Research Award. Regulation of serotonin1A, glucocorticoid, and mineralocorticoid receptor in rat and human hippocampus: implications for the neurobiology of depression. Biol Psychiatry 1998; 43 (08) 547-573
    CrossrefPubMedGoogle Scholar
  • 8 McCormack PL. Vilazodone: a review in major depressive disorder in adults. Drugs 2015; 75 (16) 1915-1923
    CrossrefPubMedGoogle Scholar
  • 9 Bang-Andersen B, Ruhland T, Jørgensen M. et al. Discovery of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): a novel multimodal compound for the treatment of major depressive disorder. J Med Chem 2011; 54 (09) 3206-3221
    CrossrefPubMedGoogle Scholar
  • 10 Narita N, Hashimoto K, Tomitaka S, Minabe Y. Interactions of selective serotonin reuptake inhibitors with subtypes of sigma receptors in rat brain. Eur J Pharmacol 1996; 307 (01) 117-119
    CrossrefPubMedGoogle Scholar
  • 11 Bermack JE, Debonnel G. The role of sigma receptors in depression. J Pharmacol Sci 2005; 97 (03) 317-336
    CrossrefPubMedGoogle Scholar
  • 12 Uchida N, Ujike H, Tanaka Y. et al. A variant of the sigma receptor type-1 gene is a protective factor for Alzheimer disease. Am J Geriatr Psychiatry 2005; 13 (12) 1062-1066
    CrossrefPubMedGoogle Scholar
  • 13 Junien JL, Roman F, Defaux JP. et al. JO-1784, a new selective ligand for sigma-1 sites-characteristics and functional-activity. Eur J Pharmacol 1990; 183: 2145-2145
    CrossrefGoogle Scholar
  • 14 Villard V, Meunier J, Chevallier N, Maurice T. Pharmacological interaction with the sigma1 (σ1)-receptor in the acute behavioral effects of antidepressants. J Pharmacol Sci 2011; 115 (03) 279-292
    CrossrefPubMedGoogle Scholar
  • 15 Hayashi T, Su TP. Sigma-1 receptor ligands: potential in the treatment of neuropsychiatric disorders. CNS Drugs 2004; 18 (05) 269-284
    CrossrefPubMedGoogle Scholar
  • 16 Skuza G, Rogóz Z. Antidepressant-like effect of combined treatment with selective sigma receptor agonists and a 5-HT1A receptor agonist in the forced swimming test in rats. Pharmacol Rep 2007; 59 (06) 773-777
    PubMedGoogle Scholar
  • 17 Bermack JE, Debonnel G. Effects of OPC-14523, a combined sigma and 5-HT1a ligand, on pre- and post-synaptic 5-HT1a receptors. J Psychopharmacol 2007; 21 (01) 85-92
    CrossrefPubMedGoogle Scholar
  • 18 Bermack JE, Haddjeri N, Debonnel G. Effects of the potential antidepressant OPC-14523 [1-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-methoxy-3,4-dihydro-2-quinolinone monomethanesulfonate] a combined sigma and 5-HT1A ligand: modulation of neuronal activity in the dorsal raphe nucleus. J Pharmacol Exp Ther 2004; 310 (02) 578-583
    CrossrefPubMedGoogle Scholar
  • 19 Możdżeń E, Papp M, Gruca P. et al. 1,2,3,4-Tetrahydroisoquinoline produces an antidepressant-like effect in the forced swim test and chronic mild stress model of depression in the rat: Neurochemical correlates. Eur J Pharmacol 2014; 729: 107-115
    CrossrefPubMedGoogle Scholar
  • 20 Chodkowski A, Wróbel MZ, Turło J. et al. Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT1A activity. Part 4. Eur J Med Chem 2015; 90: 21-32
    CrossrefPubMedGoogle Scholar
  • 21 Kiss B, Horváth A, Némethy Z. et al. Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile. J Pharmacol Exp Ther 2010; 333 (01) 328-340
    CrossrefPubMedGoogle Scholar
  • 22 Frankel JS, Schwartz TL. Brexpiprazole and cariprazine: distinguishing two new atypical antipsychotics from the original dopamine stabilizer aripiprazole. Ther Adv Psychopharmacol 2017; 7 (01) 29-41
    CrossrefPubMedGoogle Scholar